Dudediligence.

Karyopharm Therapeutics Inc

KPTINASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$38.8MSep ’24$30.5MDec ’24$30.0MMar ’25$37.9MJun ’25$44.0MSep ’25$34.1MDec ’25$35.1MMar ’26$33.4MJun ’26
Net income, by quarter
−$32.1MSep ’24−$30.8MDec ’24−$23.5MMar ’25−$37.3MJun ’25−$33.1MSep ’25−$102.2MDec ’25−$22.4MMar ’26−$67.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$209.8M$157.1M$146.0M$145.2M$146.1M
Operating income−$98.3M−$142.2M−$129.5M−$119.4M−$90.7M
Net income−$124.1M−$165.3M−$143.1M−$76.4M−$196.0M
Operating cash flow−$107.1M−$149.6M−$92.7M−$127.5M−$75.4M
Free cash flow−$107.3M−$149.7M−$92.7M−$127.6M−$75.4M
Cash$190.5M$135.2M$52.2M$62.5M$60.5M
Debt$169.3Mnone on filenone on filenone on filenone on file
Shares outstanding75.7M113.2M114.9M8.4M18.3M